T-MAXIMUM
T-Maximum develops CAR-T cell therapies for the treatment of brain tumors. T-Maximum's gene-editing allogeneic immune cell therapy adopts the version 3.0 program with completely independent intellectual property rights to realize allogeneic universal CAR-T therapy and solve the risk of graft-versus-host disease and rejection of allogeneic immune cells.
T-MAXIMUM
Industry:
Biotechnology Health Care Product Research
Founded:
2017-01-01
Address:
Suzhou, Jiangsu, China
Country:
China
Website Url:
http://www.t-maximum.com
Status:
Active
Contact:
400-9600-652
Email Addresses:
[email protected]
Total Funding:
0
Investors List
Hongfeng Investment Management
Hongfeng Investment Management investment in Angel Round - T-Maximum
Haibang Capital
Haibang Capital investment in Angel Round - T-Maximum
Official Site Inspections
http://www.t-maximum.com
- Host name: 155.102.130.202
- IP address: 155.102.130.202
- Location: San Mateo United States
- Latitude: 37.5517
- Longitude: -122.33
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94402
More informations about "T-Maximum"
T-Maximum 2025 Company Profile: Valuation, Funding …
Information on valuation, funding, cap tables, investors, and executives for T-Maximum. Use the PitchBook Platform to explore the full profile.See details»
T-MAXIMUM Biopharmaceuticals (Suzhou) Co., Ltd.
May 20, 2025 About T-Maximum Pharmaceutical T-Maximum Pharmaceutical was founded in 2017, and two core laboratories located in China and the United States. T-Maximum Pharmaceutical is leading the development of universal …See details»
T-MAXIMUM PHARMACEUTICAL - LinkedIn
T-MAXIMUM Pharmaceutical (T-MAXIMUM) is a clinical-stage biotech company based in Suzhou, China focusing on the development of allogeneic universal CAR-T cell therapies for solid tumors. It’s ...See details»
WuXi ATU and T-MAXIMUM Announce Strategic …
June 6, 2023 – Boston, Massachusetts. WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and T-MAXIMUM today signed a strategic collaboration …See details»
GenScript Biotech and T-MAXIMUM Biotech Form Strategic …
Aug 9, 2023 T-MAXIMUM Biotech is a clinical-stage cell therapy development company with core technology published in top journals such as Nature, Nature Biotechnology, Nature …See details»
T-Maximum Pharmaceutical - VentureRadar
T-Maximum Pharmaceutical is a biotechnology company specializing in the development of universal cell-based therapies. The firm focuses on creating allogeneic CAR-T therapies using …See details»
Home - T-Maximus
Years Experience 0 + Why Us Our Commitment to Excellence At T-Maximus, we go the extra mile, providing recruitment solutions that transcend boundaries and consistently exceed client expectations. With a focus on the customer, …See details»
T-MAXIMUM Biotech - 运营 - T-MAXIMUM PHAMACEUTICAL
Explore solutions to uncurable diseases · T-MAXIMUM Pharmaceutical (T-MAXIMUM) is a clinical-stage biotech company focusing on the development of allogeneic universal CAR-T …See details»
T-Maximum - Funding, Financials, Valuation & Investors
Aug 20, 2021 T-Maximum has raised 1 round. This was a Angel round raised on Aug 20, 2021. T-Maximum is funded by 2 investors. Hongfeng Investment Management and Haibang Capital …See details»
MT-026 (T-Maximum) - Drug Targets, Indications, Patents
Jun 21, 2025 MT-026 (T-Maximum): a IL-13Rα2 inhibitors, Gene transference, T lymphocyte replacements Drug, Initially developed by T-MAXIMUM Biopharmaceuticals (Suzhou) Co., …See details»
药明生基与茂行生物就通用型CAR-T产品达成战略合作｜Bilingual …
Jun 9, 2023 药明康德内容团队编辑日前，药明生基与茂行生物美国公司T-MAXIMUM Pharmaceutical（简称：T-MAXIMUM）共同宣布达成战略合作协议。药明生基将为茂行生物 ...See details»
T-MAXIMUM Pharmaceutical-动脉网 - vbdata.cn
T-MAXIMUM Pharmaceutical是一家临床阶段的细胞疗法开发企业，致力于新型免疫细胞治疗技术的开发。See details»
T-Maximum - Crunchbase
T-Maximum develops CAR-T cell therapies for the treatment of brain tumors.See details»
茂行生物与药明生基就MT-027通用型CAR-T产品达成战略合作医药 …
Jun 9, 2023 茂行生物美国公司T-MAXIMUM Pharmaceutical Inc（简称：T-MAXIMUM）与药明生基共同宣布达成战略合作协议。 药明生基将为茂行生物的MT-027通用型CAR-T细胞产品在 …See details»
药明生基与茂行生物就MT-027 通用型CAR-T产品达成战略合作_药 …
2023年6月6日，美国马萨诸塞州波士顿 药明生基与茂行生物美国公司T-MAXIMUM Pharmaceutical Inc（简称：T-MAXIMUM）共同宣布达成战略合作协议。 药明生基将为茂行生 …See details»
GenScript Biotech and T-MAXIMUM Biotech Form Strategic …
Aug 9, 2023 T-MAXIMUM Biotech targets solid tumors with universal cell therapy T-MAXIMUM Biotech is a clinical-stage cell therapy development company with core technology published …See details»
Limits and specifications for Microsoft Teams
Apr 17, 2025 This article describes the limits, specifications, and other requirements that apply to Microsoft Teams.See details»
How to Use LinkedIn Hashtags for Maximum Impact Plus Examples
4 days ago Learn how to use LinkedIn hashtags for reach, targeting, engagement, and content discovery with 40+ industry-specific hashtags to grow your business in 2025.See details»
T-Maximum - Tech Stack, Apps, Patents & Trademarks - Crunchbase
T-Maximum develops CAR-T cell therapies for the treatment of brain tumors.See details»
FIDF chair on his way out amid mismanagement allegations: 'The ...
2 days ago The organization insisted fundraising remains strong because backers “understand the critical and vital role FIDF plays,” and claimed continued “professional and public …See details»